Philip Brodak, MD
Urology · Murrieta, CANPI 1417057514
Payments from drug & device makers
Across 509 payments — averaging $1436.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring International Pharmascience Center US$376K
- Sumitomo Pharma America, Inc.$164K
- Ferring Pharmaceuticals AS$126K
- Neotract Inc.$19K
- Arrow International, Inc.$14K
- Teleflex LLC$11K
- plus $22K from 53 others
Across 2 payments — averaging $16,784 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seikagaku Corporation$34K
What the payments were for
- Consulting fees$7,28037%
- Travel & lodging$6243%
- Food & beverage$11,16256%
- Education$6603%
- Gifts$750%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nubeqa$3,258
- XTANDI$2,500
- Xofigo$1,800
- TITAN$610
- AQUABEAM SYSTEM$239
- Prolaris$211
- ALTIS$139
- CAMCEVI$124
- AMS 700 CXR RTE KIT$122
- XIAFLEX$117
- COLOGUARD$116
- UroLift$115
- Erleada$114
- Desara$110
- ORGOVYX$109
- INTERSTIM$103
- AquaBeam Robotic System$102
- rezum Generator$102
How this compares
$731,412 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 17 | $237,952 |
| Lupron DepotLeuprolide Acetate | 12 | $140,147 |
| XgevaDenosumab | 42 | $127,073 |
| GemtesaVibegron | 112 | $121,432 |
| OrgovyxRelugolix | 45 | $118,467 |
| MyrbetriqMirabegron | 127 | $118,249 |
| ElmironPentosan Polysulfate Sodium | 25 | $47,873 |
| XyostedTestosterone Enanthate | 18 | $26,712 |
| Testosterone Cypionate | 388 | $21,853 |
| Potassium Citrate ErPotassium Citrate | 125 | $19,661 |
| Testosterone | 68 | $17,950 |
| Mirabegron ErMirabegron | 18 | $12,490 |
| Tamsulosin Hcl | 584 | $11,809 |
| BotoxOnabotulinumtoxina | 11 | $9,539 |
| Oxybutynin Chloride ErOxybutynin Chloride | 241 | $8,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $164,290 | $239,899157 claims |
| BayerNubeqa | $5,560 | $237,95217 claims |
| AbbVieLupron Depot, Botox, Armour Thyroid | $869 | $151,31045 claims |
| AmgenXgeva | $134 | $127,07342 claims |
| Astellas Pharma US IncMyrbetriq | $3,223 | $118,249127 claims |
| Antares Pharma, Inc.Xyosted | $581 | $26,71218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Murrieta
- Monisha CrisellMurrieta$582K
- Richard ConnerMurrieta$372K
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.